Literature DB >> 14715179

Early interleukin-1 receptor antagonist elevation in patients with acute myocardial infarction.

Giuseppe Patti1, Andrea D'Ambrosio, Simona Mega, Gabriele Giorgi, Enrico Maria Zardi, Domenico Maria Zardi, Giordano Dicuonzo, Aldo Dobrina, Germano Di Sciascio.   

Abstract

OBJECTIVES: We sought to evaluate interleukin-1 receptor antagonist (IL-1Ra) levels in patients with ST-segment elevation acute myocardial infarction (AMI) upon emergency department (ED) admission in order to assess the sensitivity of such a determination by comparison with common markers of myocardial necrosis.
BACKGROUND: Inflammatory markers are elevated in patients with unstable coronary syndromes, but IL-1Ra levels during the early phases of AMI have not been previously investigated.
METHODS: Levels of IL-1Ra were measured in 44 consecutive patients with AMI and compared with creatine kinase (CK), CK-MB, troponin I, myoglobin, and C-reactive protein (CRP).
RESULTS: Upon admission, 82% of patients had elevated (>230 pg/ml) IL-1Ra levels, compared with 41% of patients with raised CK (p = 0.001), CK-MB (45%, p = 0.002), troponin I (57%, p = 0.027), myoglobin (48%, p = 0.004), and CRP (57%, p = 0.019) levels. The IL-1Ra values were significantly higher in patients with heralded AMI than in those without pre-infarction angina (671 vs. 320 pg/ml, p = 0.013). The sensitivity of IL-1Ra determination increased to 86% when chest pain duration was < or =3 h and to 91% if heralded infarction occurred.
CONCLUSIONS: Our study indicates that, unlike markers of necrosis, an increase of IL-1Ra levels occurs early in patients with AMI, is more significant in those with heralded infarction and symptom onset < or =3 h, and precedes the release of markers of necrosis. Thus, IL-1Ra determination may be an important early adjuvant toward the diagnosis of AMI in the ED.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14715179     DOI: 10.1016/j.jacc.2003.07.032

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  13 in total

Review 1.  Examining the Role of and Treatment Directed at IL-1β in Atherosclerosis.

Authors:  Razi Khan; Eric Rheaume; Jean-Claude Tardif
Journal:  Curr Atheroscler Rep       Date:  2018-09-15       Impact factor: 5.113

2.  Effects of drug-eluting stents on systemic inflammatory response in patients with unstable angina pectoris undergoing percutaneous coronary intervention.

Authors:  Nihat Ozer; Burak Tangurek; Fatih Firat; Songul Ozer; Zeynep Tartan; Recep Ozturk; Batuhan Ozay; Figen Ciloglu; Hale Yilmaz; Nese Cam
Journal:  Heart Vessels       Date:  2008-04-04       Impact factor: 2.037

Review 3.  The role of IL-1 in the pathogenesis of heart disease.

Authors:  Marcin Bujak; Nikolaos G Frangogiannis
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2009-05-29       Impact factor: 4.291

4.  Cytoprotective activated protein C averts Nlrp3 inflammasome-induced ischemia-reperfusion injury via mTORC1 inhibition.

Authors:  Sumra Nazir; Ihsan Gadi; Moh'd Mohanad Al-Dabet; Ahmed Elwakiel; Shrey Kohli; Sanchita Ghosh; Jayakumar Manoharan; Satish Ranjan; Fabian Bock; Ruediger C Braun-Dullaeus; Charles T Esmon; Tobias B Huber; Eric Camerer; Chris Dockendorff; John H Griffin; Berend Isermann; Khurrum Shahzad
Journal:  Blood       Date:  2017-09-07       Impact factor: 22.113

5.  Mathematical modeling and stability analysis of macrophage activation in left ventricular remodeling post-myocardial infarction.

Authors:  Yunji Wang; Tianyi Yang; Yonggang Ma; Ganesh V Halade; Jianqiu Zhang; Merry L Lindsey; Yu-Fang Jin
Journal:  BMC Genomics       Date:  2012-10-26       Impact factor: 3.969

6.  Proteomic analysis of whole human saliva detects enhanced expression of interleukin-1 receptor antagonist, thioredoxin and lipocalin-1 in cigarette smokers compared to non-smokers.

Authors:  Kala Jessie; Wei Wei Pang; Zubaidah Haji; Abdul Rahim; Onn Haji Hashim
Journal:  Int J Mol Sci       Date:  2010-11-09       Impact factor: 5.923

7.  Effect of gene environment interactions on lung function and cardiovascular disease in COPD.

Authors:  Tillie-Louise Hackett; Dorota Stefanowicz; Farzian Aminuddin; Don D Sin; John E Connett; Nicholas R Anthonisen; Peter D Paré; Andrew J Sandford
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2011-05-10

8.  Impact of an interleukin-1 receptor antagonist and erythropoietin on experimental myocardial ischemia/reperfusion injury.

Authors:  Christina Grothusen; Angelika Hagemann; Tim Attmann; Jan Braesen; Ole Broch; Jochen Cremer; Jan Schoettler
Journal:  ScientificWorldJournal       Date:  2012-05-02

9.  Intracellular function of interleukin-1 receptor antagonist in ischemic cardiomyocytes.

Authors:  Elena Vecile; Aldo Dobrina; Fadi N Salloum; Benjamin W Van Tassell; Antonella Falcione; Edoardo Gustini; Samuele Secchiero; Sergio Crovella; Gianfranco Sinagra; Nicoletta Finato; Martin J Nicklin; Antonio Abbate
Journal:  PLoS One       Date:  2013-01-08       Impact factor: 3.240

10.  Inflammatory markers in acute myocardial infarction and the correlation with the severity of coronary heart disease.

Authors:  Nicoleta Oprescu; Miruna Mihaela Micheu; Alexandru Scafa-Udriste; Nicoleta-Monica Popa-Fotea; Maria Dorobantu
Journal:  Ann Med       Date:  2021-12       Impact factor: 4.709

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.